v3.26.3
OTHER ASSETS
9 Months Ended
Sep. 30, 2026
OTHER ASSETS  
OTHER ASSETS

NOTE 5 – OTHER ASSETS

 

On November 28, 2025, the Company entered into an Exclusive Intellectual Property License Agreement (the “License Agreement”) with Fidelion Diagnostics Pte. Ltd. (“Fidelion”), pursuant to which the Company received an exclusive, irrevocable license to use, develop, manufacture, market, distribute, and sell products utilizing the VitaGuard™ minimal residual disease (“MRD”) liquid biopsy platform in the member states of the Association of Southeast Asian Nations (“ASEAN”). The License Agreement was entered into together with the Share Subscription and Shareholders’ Agreement between the Company and Fidelion, among others, whereby Fidelion issued to the Company 180 Ordinary Shares (approximately 15% of Fidelion’s share capital) and the Company issued 392,329 shares of its restricted common stock to Fidelion (approximately 16.6% of the Company’s issued and outstanding common stock). 

 

In consideration for the license, the Company agreed to pay Fidelion a total license fee of $2,000,000 in 24 equal monthly instalments of $83,333, commencing in December 2025. Delivery and verification of the licensed technology package remain in progress (see Part II, Item 1A). The Company records each instalment as it falls due as a deposit toward the license within Other Assets, classified as a non-current asset, and has not recognized the license rights as a separate intangible asset as of September 30, 2026. As of September 30, 2026, instalments of $833,330 had fallen due, of which $504,330 remained unpaid and is included in other payables (Note 11). The remaining instalments of $1,166,670, of which $999,996 fall due within the next twelve months, are a commitment of the Company and are not recognized in the condensed consolidated balance sheet.